10x Genomics, Inc. (NASDAQ:TXG) Shares Acquired by Trexquant Investment LP

Trexquant Investment LP lifted its position in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 196.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 594,611 shares of the company's stock after purchasing an additional 393,854 shares during the quarter. Trexquant Investment LP owned about 0.49% of 10x Genomics worth $8,539,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TXG. Signaturefd LLC grew its stake in shares of 10x Genomics by 424.6% in the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company's stock valued at $26,000 after buying an additional 1,452 shares during the period. Blue Trust Inc. grew its position in 10x Genomics by 73.1% in the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock worth $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC grew its position in 10x Genomics by 65.2% in the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after acquiring an additional 1,330 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in 10x Genomics during the fourth quarter worth $52,000. Finally, SRS Capital Advisors Inc. raised its position in 10x Genomics by 817.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,853 shares of the company's stock valued at $70,000 after purchasing an additional 4,324 shares during the period. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TXG shares. Citigroup cut their price objective on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Canaccord Genuity Group reduced their price target on shares of 10x Genomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Barclays decreased their price objective on shares of 10x Genomics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. JPMorgan Chase & Co. dropped their target price on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. Finally, UBS Group decreased their price target on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $20.21.

Remove Ads

Insider Activity

In other news, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now owns 879,482 shares in the company, valued at approximately $9,735,865.74. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company's stock, valued at $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company's stock.

10x Genomics Stock Up 21.4 %

10x Genomics stock traded up $1.53 during trading on Wednesday, reaching $8.67. The stock had a trading volume of 5,755,955 shares, compared to its average volume of 2,147,462. 10x Genomics, Inc. has a 52-week low of $6.78 and a 52-week high of $36.46. The business has a 50 day moving average price of $10.70 and a 200 day moving average price of $14.15. The stock has a market cap of $1.06 billion, a PE ratio of -5.70 and a beta of 2.01.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, equities analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.